A Phase 1, Open-Label, Sequential Cross-over, Bioavailability/Bioequivalence Study to Compare the Pharmacokinetics of Oral Cladribine With the Reference Listed Drug, Intravenous Cladribine
Phase 1 Terminated
3 enrolled
CLAG-M or FLAG-Ida Chemotherapy and Reduced-Intensity Conditioning Donor Stem Cell Transplant for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Chronic Myelomonocytic Leukemia
Phase 1 Recruiting
120 enrolled
TCCA
Phase 1 Recruiting
28 enrolled
Lintuzumab-Ac225 in Combination with Cladribine + Cytarabine + Filgastrim + Mitoxantrone (CLAG-M) for Relapsed/Refractory Acute Myeloid Leukemia
Phase 1 Completed
26 enrolled
Venetoclax-Navitoclax With Cladribine-based Salvage Therapy in Patients With Relapsed/Refractory Acute Myeloid Leukemia
Phase 1 Withdrawn
Continuous Infusion Chemotherapy (CI-CLAM) for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia or Other High-Grade Myeloid Neoplasms
Phase 1 Terminated
13 enrolled
GM-CLAG in Relapsed/Refractory FLT3-mutated AML
Phase 1 Withdrawn
Treatment of Macroglobulinemic Lymphoma With 2CdA, Cyclophosphamide and Rituximab
Phase 1 Completed
14 enrolled
Rituximab, Cladribine, and Temsirolimus in Treating Patients With Newly Diagnosed Mantle Cell Lymphoma
Phase 1 Completed
74 enrolled
Bortezomib (VELCADE), Cladribine and Rituximab (VCR) in Mantle Cell Lymphoma (PSHCI 10-011)
Phase 1 Unknown
13 enrolled
Chemotherapy Followed by Radiation Therapy in Treating Patients With Malignant Glioma
Phase 1 Completed
Bryostatin 1 Plus Cladribine in Treating Patients With Relapsed Chronic Lymphocytic Leukemia
Phase 1 Completed
80 enrolled
Cladribine, Cytarabine, and Imatinib Mesylate in Treating Patients With Refractory or Relapsed Acute Myeloid Leukemia or Blastic Phase Chronic Myelogenous Leukemia
Phase 1 Completed
18 enrolled
CLAG ATRA AML
Phase 1 Completed
11 enrolled
Stem Cell Transplantation in Treating Patients With Hematologic Cancer
Phase 1 Completed